98%
921
2 minutes
20
Background: VAV1 is an intracellular signal transduction protein that plays a significant role in signal transduction in T cells. Several studies suggest that VAV1 signaling plays significant roles in allograft rejection. The aim of this study was to examine the association between VAV1 gene polymorphisms and renal allograft function.
Methods: The study included 270 patients after allograft renal transplantation. We examined the associations between VAV1 gene polymorphisms and complications after transplantation, such as delayed graft function, acute rejection, and chronic allograft dysfunction.
Results: There were no statistically significant associations between VAV1 genotypes and delayed graft function and chronic allograft dysfunction. Among patients with acute allograft rejection, we observed decreased frequencies of VAV1 rs2546133 TT and CT genotypes (P = .03) and T allele (P = .02), as well as VAV1 rs2617822 GG and AG genotypes (P = .05) and G allele (P = 0.04). In the multivariate regression analysis, the higher number of VAV1 rs2546133 T alleles showed a protective effect against the acute rejection in kidney allograft recipients.
Conclusions: The results of our study suggest that polymorphisms in the VAV1 gene are associated with kidney allograft rejection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2021.04.003 | DOI Listing |
Front Immunol
July 2025
Clinical Immunology, Inflammation and Allergy Laboratory (LICIA), Faculty of Medicine and Pharmacy, University of Hassan II Casablanca, Casablanca, Morocco.
Background: Common Variable Immunodeficiency (CVID) is the most prevalent symptomatic inborn errors of immunity (IEI), characterized by impaired antibody production, recurrent infections, and immune dysregulation. While extensively studied in Western populations, data from North Africa remains scarce. This study provides the first comprehensive evaluation of the clinical, immunological, and genetic landscape of CVID in a Moroccan nationwide cohort.
View Article and Find Full Text PDFFront Immunol
July 2025
Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Background: Chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) are closely associated. However, membranous nephropathy (MN), one of the causes of CKD, may contribute to NAFLD through abnormalities in lipid metabolism.
Methods: 93 patients diagnosed with MN by renal biopsy and admitted to Henan Provincial People's Hospital between August 2021 and August 2022 were enrolled in this study.
Am J Hematol
September 2025
Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Nodal follicular helper T-cell (T ) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole-exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2 ) and novel ones (TET3, KMT2D). TET2, IDH2 , DNMT3A co-mutated AITLs had poor prognosis (p < 0.
View Article and Find Full Text PDFCurr Pharm Biotechnol
May 2025
Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Introduction: Hydroxysafflor Yellow A (HSYA), known for its anti-inflammatory effects in cardiovascular diseases, has also been shown to reduce adiposity and improve metabolic disorders in diet-induced obese (DIO) mice. However, the molecular mechanisms underlying its anti-obesity effects, particularly whether they are mediated through immune-inflammatory pathways, remain unclear. This study aims to identify the key molecular mechanisms involved in HSYA's anti-obesity action.
View Article and Find Full Text PDFSovrem Tekhnologii Med
May 2025
MD, PhD, Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologi
Unlabelled: One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques. was to evaluate the impact efficacy of "enhanced" NK cells on early metabolic rearrangements and the viability of glioblastoma cells in a patient using a tumor spheroid model.
View Article and Find Full Text PDF